WFA
ADMA icon

Wipfli Financial Advisors’s ADMA Biologics ADMA Stock Holding History

Wipfli Financial Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$1K Buy
+563
New +$1.35K ﹤0.01% 2357

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Wipfli Financial Advisors's ADMA Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in ADMA Biologics (ADMA) in Q3 2022: 563 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #2357 among its holdings.

130 funds tracked by Wall St. Rank hold ADMA as of Q3 2022.

  • Wipfli Financial Advisors held 563 shares of ADMA Biologics worth $1K as of Q3 2022.
  • ADMA Biologics was a new Wipfli Financial Advisors position in Q3 2022.
  • ADMA Biologics made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #2357 holding.
  • 130 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.